🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

964 results for “Advanced” Clear

  1. Volrustomig

    Arcus Biosciences

    Advanced Clear Cell Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  2. Zelenectide Pevedotin, BT8009, PEMBROLIZUMAB, AVELUMAB, CISPLATIN, CARBOPLATIN, GEMCITABINE

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  3. [18F]-AlF-FAPI-74

    Disc Medicine

    Advanced gastric cancer

    phase 3 small molecule active

    1 trial

  4. camizestrant, Arimidex® 1 mg Filmtabletten, IBRANCE 75 mg hard capsules, Placebo to match camizestrant, Placebo to match Arimidex, LEUPRORELIN ACETATE, IBRANCE 125 mg hard capsules, IBRANCE 75 mg film-coated tablets, IBRANCE 100 mg hard capsules, IBRANCE 75 mg hard capsules, IBRANCE 100 mg hard capsules, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, IBRANCE 125 mg hard capsules, IBRANCE 100 mg hard capsules, Camizestrant, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules, G

    AstraZeneca AB

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  5. enfortumab vedotin, VINFLUNINE , DOCETAXEL , PACLITAXEL

    Astellas Pharma GmbH

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  6. evorpacept, Herceptin 150 mg powder for concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/mL concentrate for solution for infusion, Normal Saline (Sodium Chloride)

    Ology Bioservices Ireland LTD

    Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

    phase 3 small molecule active

    1 trial

  7. fianlimab

    Regeneron UK Limited

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. innohep® 10.000 anti Xa IU/0,5mL PF.SYR. Ενέσιμο διάλυμα, innohep® 18.000 anti Xa IU/0,9mL PF.SYR. Ενέσιμο διάλυμα, innohep® 14.000 anti Xa IU/0,7mL PF.SYR. Ενέσιμο διάλυμα

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Thromboprophylaxis in patients with advanced pancreatic cancer

    phase 3 small molecule active

    1 trial

  9. normal saline solution for infusion, Ociperlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tislelizumab, Ociperlimab

    BeiGene Ireland Ltd

    Locally advanced, unresectable, or metastatic non small cell lung cancer

    phase 3 small molecule active

    1 trial

  10. relacorilant, CORT125134, Abraxane 5 mg/ml powder for dispersion for infusion.

    CORCEPT THERAPEUTICS INC

    Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

    phase 3 small molecule active

    1 trial

  11. -

    Vita (Europe) Limited

    Primary or advanced breast cancer LumA or ER+ Lobular subtypes.

    phase 2 small molecule active

    1 trial

  12. -, -, -, MK-1200, -, -

    Merck Sharp and Dohme

    Advanced solid tumor

    phase 2 small molecule active

    1 trial

  13. -, -, CIMETIDINE , ROXATIDINE , FAMOTIDINE, COMBINATIONS, PARACETAMOL , RANITIDINE , NIZATIDINE , SKB264, FAMOTIDINE , -

    Pharma Mar S.A.

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial

  14. -, -, ROXATIDINE , RANITIDINE , OSIMERTINIB , NIZATIDINE , SKB264, CIMETIDINE , FAMOTIDINE, COMBINATIONS, FAMOTIDINE , CARBOPLATIN , PARACETAMOL , PEMBROLIZUMAB , OSIMERTINIB, -

    Pharma Mar S.A.

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  15. -, Pred Forte 10 mg/ml colirio en suspensión

    AbbVie Deutschland GmbH & Co. KG

    platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.

    phase 2 small molecule active

    1 trial

  16. 177Lu girentuximab

    Telix Innovations

    Advanced Cancer

    phase 2 small molecule active

    1 trial

  17. 177Lu-PSMA I&T_IRSTIRCCS

    Istituto Gentili S.r.l.

    PSMA PET/CT positive advanced/metastatic tumours

    phase 2 small molecule active

    1 trial

  18. 2X-121

    Allarity Therapeutics

    Advanced Ovarian Cancer

    phase 2 small molecule active

    1 trial

  19. 89Zr-Trastuzumab_IJB, Herceptin 150 mg powder for concentrate for solution for infusion, TRASTUZUMAB EMTANSINE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    advanced/metastatic HER2-positive breast carcinoma

    phase 2 small molecule active

    1 trial

  20. A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

    Roche Registration Limited

    Advanced or metastatic squamous cell carcinoma of the esophagus

    phase 2 other active

    1 trial

  21. A Clinical Trial for Patients with Advanced Cancers

    Corbus Pharmaceuticals Holdings

    Advanced Solid tumour

    phase 2 other active

    1 trial

  22. A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)

    Merck Sharp and Dohme

    Cancer – Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification)

    phase 2 other active

    1 trial

  23. A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

    Cancer Prevention Pharma (Ireland) Limited

    Patients with a histilogically confirmed diagnosis of cervical squamous or adenosquamous carcinoma stage IB3 if N>=1 or II to IVA with any N stage according to FIGO 2018 and no evidence of metastatic disease (M0), without any prior anti-cancer treatment.

    phase 2 other active

    1 trial

  24. A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)

    Tyra Biosciences

    Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources